ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Is Magnesium the Missing Link in Your Heart Healthy Routine?

A Little Zinc Goes a Long Way

Supplementation with vitamin D associated with improved testosterone, erectile function among middle...

More evidence for calorie restriction’s longevity effect

Vitamin D deficiency increases risk of chronic headache

Wearable biosensors can flag illness, Lyme disease, risk for diabetes; low airplane oxygen

VIDEO: The Best Brain Foods That Help Increase Your Memory!

Iron (And More) For Lasting, Natural Energy

Affordable Care Act made cancer screening more accessible for millions, study finds

Metabolic syndrome increases the need for vitamin E

 
Print Page
Email Article

Will Pending FDA Decision OK First Lupus Drug in 52 Years?

  [ 8 votes ]   [ Discuss This Article ]
www.ProHealth.com • December 15, 2010


After applauding an advisory panel’s strong recommendation in mid-November that the FDA approve marketing of the experimental lupus drug, Benlysta™ (belimumab), the lupus community now awaits the final FDA decision – scheduled for March 10.

On November 16, after reviewing the research and listening to the moving testimony of a dozen lupus patients and their families [see video excerpts below], the FDA’s Arthritis Advisory Committee voted overwhelmingly (13 to 2) to recommend the experimental drug Benlysta for approval as a treatment for the very serious, ill understood, and hard-to-treat autoimmune disease lupus.

Excerpts from the testimonies shared at FDA panel hearing.



Why the Wait?
Importantly, Benlysta research so far appears to indicate that for some patients it can support more improvement than ‘standard care’ alone, and/or reduce the need for other drugs with harmful side effects.

But the disease takes many forms, and Benlysta does not work for all patients. For example, reportedly it didn’t help African-Americans, who are three times as likely to develop lupus as Caucasians. (For information on the latest study, a large international, placebo-controlled trial, click HERE.)

Accordingly, the FDA wanted several months’ time before they make a decision – presumably to consider the data for insights on safety & efficacy, and how that might translate into guidelines for the drug’s use before making a decision. For example, reportedly they will be taking a careful look at how the drug might best be labeled – e.g., limitations on its prescription, such as patient types/circumstances not clearly represented in the studies.  

Advocates Applaud Benlysta as Step Forward
The Nov 16 Advisory Panel recommendation was “a great day for lupus” said Lupus Foundation of America President and CEO Sandra C. Raymond.

Acknowledging that Benlysta is a first step of sorts, she said:

“Lupus is unique from person to person. We need an arsenal of treatments, and I think now we now have the opportunity to get them. Finally. After 52 years. I say to the panel, congratulations, you did the right thing.

“I say to the company, you’re pioneers. It’s like carving that path moving to the West in the 1800’s. That’s what they’ve done in Lupus. They’ve carved a path and now it’s up to the rest of the companies to come through and improve upon the kinds of medications we have right now, and on Benlysta, so that we can better treat individuals with Lupus.”

For plain language information on recent research studies & findings, see the American Lupus Foundation’s “Research Summaries” page. Each research category lists summaries starting with the most recent. Summaries of Benlysta studies are included under “Lupus Treatments.”

And for the detail oriented, following is a video by researchers discussing the different Benlysta trials conducted to date and the difficulty of studying any treatment in a patient population with such widely varying manifestations and severity.



____

Sources:
Lupus Foundation of America press release, Nov 16, 2010; LFA website and video statements; commentaries of various drug industry and market blogs following Benlysta's prospects.




Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Ultra ATP+, Double Strength Mitochondria Ignite™ with NT Factor®

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

The Remarkable Benefits of Reishi Medicinal Mushrooms The Remarkable Benefits of Reishi Medicinal Mushrooms
Health Benefits Are Brewing in Green Tea Health Benefits Are Brewing in Green Tea
Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery
Can Glycine + Amino Acids Be the Secret to Deep, Rejuvenating Sleep? Can Glycine + Amino Acids Be the Secret to Deep, Rejuvenating Sleep?
The Guaifenesin Story: A centuries-old bark extract used for clearing the airways – now key to a popular FM symptom-reversal protocol The Guaifenesin Story: A centuries-old bark extract used for clearing the airways – now key to a popular FM symptom-reversal protocol

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map